Objective: To determine the accuracy of prostate cancer detection by using magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion image-guided prostate biopsy.
Materials and Methods: Retrospective data were collected from the patients that underwent targeted prostate biopsy guided by MRI-TRUS fusion imaging of the prostate between January 2017 and October 2018. The data including age, serum prostate-specific antigen (PSA) levels, PSA density, prostate size, lesion size from multiparametric magnetic resonance imaging of the prostate (mpMRI), Prostate Imaging and Reporting Archiving Data System score (PI-RADS), number of targeted core biopsy, and result from the pathological diagnosis were collected. Detection rate of prostate cancer was analyzed.
Results: Ninety-five prostate cancer suspected patients underwent prostate biopsy for 143 lesions. Patients’ analyses showed better overall detection rate of prostate cancer from the MRI-TRUS fusion image-guided prostate biopsy compared to the extended 12-core systematic biopsy at 49.5% versus 17.9%. Significant prostate cancer with a Gleason score of more than 6 was detected by MRI-TRUS fusion image-guided prostate biopsy at 33.7%. Prostate cancer detection rates from MRI-TRUS fusion image-guided prostate biopsy categorized by PI-RADS score 3, 4, and 5 were 21%, 48%, and 74%, respectively, which showed statistically significant detection rate with higher PI-RADS score (p<0.001).
Conclusion: The present study showed better prostate cancer detection rate using MRI-TRUS fusion image-guide prostate biopsy with correlation to higher PI-RADS score.
Keywords: Gleason score; PI-RADS score; mpMRI; MRI-TRUS fusion image-guided prostate biopsy
Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate
